Cargando…
Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer
Many studies have addressed the clinical value of pS2 as a marker of hormone responsiveness and of cathepsin D (Cath D) as a prognostic factor in breast cancer. Because pS2 and Cath D are both oestrogen induced in human breast cancer cell lines, we studied the influence of the menstrual cycle phase...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362656/ https://www.ncbi.nlm.nih.gov/pubmed/10070889 http://dx.doi.org/10.1038/sj.bjc.6690145 |
_version_ | 1782153507409756160 |
---|---|
author | Pujol, P Daurès, J-P Brouillet, J-P Maudelonde, T Rochefort, H Grenier, J |
author_facet | Pujol, P Daurès, J-P Brouillet, J-P Maudelonde, T Rochefort, H Grenier, J |
author_sort | Pujol, P |
collection | PubMed |
description | Many studies have addressed the clinical value of pS2 as a marker of hormone responsiveness and of cathepsin D (Cath D) as a prognostic factor in breast cancer. Because pS2 and Cath D are both oestrogen induced in human breast cancer cell lines, we studied the influence of the menstrual cycle phase and menopausal status at the time of surgery on the levels of these proteins in breast cancer. A population of 1750 patients with breast cancer, including 339 women in menstrual cycle, was analysed. Tumoral Cath D and pS2 were measured by radioimmunoassay. Serum oestradiol (E2), progesterone (Pg), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels at the day of surgery were used to define the hormonal phase in premenopausal women. There was a trend towards a higher mean pS2 level in the follicular phase compared with the luteal phase (17 ng mg(−1)and 11 ng mg(−1)respectively, P= 0.09). Mean pS2 was lower in menopausal patients than in women with cycle (8 ng mg(−1)and 14 ng mg(−1)respectively, P= 0.0001). No differences in mean Cath D level were observed between the different phases of the menstrual cycle, or between pre- and post-menopausal women. In the overall population, pS2 was slightly positively associated with E2 and Pg levels and negatively associated with FSH and LH, probably reflecting the link between pS2 and menopausal status. In premenopausal women, no association was found between pS2 and E2, Pg, FSH or LH levels. There were no correlations between Cath D level and circulating hormone levels in the overall population. However, in the subgroup of premenopausal women with ER-positive (ER+) tumours, E2 was slightly associated with both pS2 and Cath D, consistent with oestrogen induction of these proteins in ER+ breast cancer cell lines. There are changes in pS2 level in breast cancer throughout the menstrual cycle and menopause. This suggests that the choice of the pS2 cut-off level should take the hormonal status at the time of surgery into account. In contrast, the level of Cath D is unrelated to the menstrual cycle and menopausal status. 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2362656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23626562009-09-10 Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer Pujol, P Daurès, J-P Brouillet, J-P Maudelonde, T Rochefort, H Grenier, J Br J Cancer Regular Article Many studies have addressed the clinical value of pS2 as a marker of hormone responsiveness and of cathepsin D (Cath D) as a prognostic factor in breast cancer. Because pS2 and Cath D are both oestrogen induced in human breast cancer cell lines, we studied the influence of the menstrual cycle phase and menopausal status at the time of surgery on the levels of these proteins in breast cancer. A population of 1750 patients with breast cancer, including 339 women in menstrual cycle, was analysed. Tumoral Cath D and pS2 were measured by radioimmunoassay. Serum oestradiol (E2), progesterone (Pg), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels at the day of surgery were used to define the hormonal phase in premenopausal women. There was a trend towards a higher mean pS2 level in the follicular phase compared with the luteal phase (17 ng mg(−1)and 11 ng mg(−1)respectively, P= 0.09). Mean pS2 was lower in menopausal patients than in women with cycle (8 ng mg(−1)and 14 ng mg(−1)respectively, P= 0.0001). No differences in mean Cath D level were observed between the different phases of the menstrual cycle, or between pre- and post-menopausal women. In the overall population, pS2 was slightly positively associated with E2 and Pg levels and negatively associated with FSH and LH, probably reflecting the link between pS2 and menopausal status. In premenopausal women, no association was found between pS2 and E2, Pg, FSH or LH levels. There were no correlations between Cath D level and circulating hormone levels in the overall population. However, in the subgroup of premenopausal women with ER-positive (ER+) tumours, E2 was slightly associated with both pS2 and Cath D, consistent with oestrogen induction of these proteins in ER+ breast cancer cell lines. There are changes in pS2 level in breast cancer throughout the menstrual cycle and menopause. This suggests that the choice of the pS2 cut-off level should take the hormonal status at the time of surgery into account. In contrast, the level of Cath D is unrelated to the menstrual cycle and menopausal status. 1999 Cancer Research Campaign Nature Publishing Group 1999-02 /pmc/articles/PMC2362656/ /pubmed/10070889 http://dx.doi.org/10.1038/sj.bjc.6690145 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Pujol, P Daurès, J-P Brouillet, J-P Maudelonde, T Rochefort, H Grenier, J Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer |
title | Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer |
title_full | Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer |
title_fullStr | Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer |
title_full_unstemmed | Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer |
title_short | Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer |
title_sort | time at surgery during menstrual cycle and menopause affects ps2 but not cathepsin d levels in breast cancer |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362656/ https://www.ncbi.nlm.nih.gov/pubmed/10070889 http://dx.doi.org/10.1038/sj.bjc.6690145 |
work_keys_str_mv | AT pujolp timeatsurgeryduringmenstrualcycleandmenopauseaffectsps2butnotcathepsindlevelsinbreastcancer AT dauresjp timeatsurgeryduringmenstrualcycleandmenopauseaffectsps2butnotcathepsindlevelsinbreastcancer AT brouilletjp timeatsurgeryduringmenstrualcycleandmenopauseaffectsps2butnotcathepsindlevelsinbreastcancer AT maudelondet timeatsurgeryduringmenstrualcycleandmenopauseaffectsps2butnotcathepsindlevelsinbreastcancer AT rocheforth timeatsurgeryduringmenstrualcycleandmenopauseaffectsps2butnotcathepsindlevelsinbreastcancer AT grenierj timeatsurgeryduringmenstrualcycleandmenopauseaffectsps2butnotcathepsindlevelsinbreastcancer |